Sofinnova Partners – a leading European venture capital firm in life sciences based in Paris, London, and Milan – announced it had raised €1.2 billion across its platform of investment strategies over the past year, including over €1 billion secured in the last quarter.
This achievement brings the firm’s assets under management (AUM) to over €4 billion, cementing its position as a leading backer of transformative innovation in healthcare and sustainability. Further details on individual funds will be disclosed upon their final closing.
Sofinnova’s latest funds attracted significant commitments from leading institutional investors, sovereign wealth funds, corporations, and family offices, underscoring strong investor confidence in the firm’s ability to identify and nurture high-potential opportunities.
In the past decade, Sofinnova has built one of the most experienced, globally connected teams in life sciences investing. And the firm comprises over 80 professionals, including 25 investment partners with deep sector expertise. Plus, it is an international team, spanning 24 nationalities across three European offices, with presence in key innovation hubs worldwide.
As Sofinnova expands its reach and sharpens its investment approach, it embraces cutting-edge technology to enhance decision-making. The firm has recently launched an AI-powered platform, built over the last five years, called Sofinnova.ai, which is transforming how it sources, analyzes, invests in, and supports breakthrough science and entrepreneurs. By utilizing advanced data analytics and machine learning, Sofinnova is further strengthening its ability to identify disruptive innovations and accelerate the development of pioneering life sciences companies.
KEY QUOTE:
“All seven of Sofinnova’s investment strategies—from incubation to later-stage growth, spanning biotech, medtech, industrial biotech and digital medicine—have capital to back the next generation of life sciences companies. With the new funds, we anticipate supporting 50 to 60 new companies, empowering a new wave of entrepreneurs tackling some of the world’s most pressing health and sustainability challenges.”
– Antoine Papiernik, Chairman and Managing Partner of Sofinnova Partners
